MedTrace Logo

Can we Rely on HLA to Predict Resistance to Biological Therapy in IBD Patients

NCT05040854 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2021-09-16

No results posted yet for this study

Summary

The investigators propose an observational study including patients with inflammatory bowel disease under biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23 (Ustekinumab), followed by an external Gastroenterology consultation at Centro Hospitalar Tondela-Viseu.

Conditions

  • Inflammatory Bowel Diseases

Interventions

GENETIC

HLA-DQA1*05 and DRB1

All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1

Sponsors & Collaborators

  • Centro Hospitalar Tondela-Viseu

    lead OTHER

Principal Investigators

  • Paula Ministro, MD · Centro Hospitalar Tondela-Viseu

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2024-04-01
Completion
2024-07-01

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05040854 on ClinicalTrials.gov